The Latest Breaking News from diabetes

Eli Lilly's weight-loss and diabetes drugs Zepbound and Mounjaro should drive the biopharma stock much higher, said a Morgan Stanley analyst.

Researchers believe that if patients who are likely to respond well to antiseptic mouthwash could be identified, it would be an easy-to-use treatment for people with periodontic-linked diseases.

Eli Lilly (LLY) saw steady growth in its last reported quarter, driven by sales from its popular diabetes drug Mounjaro. The stock has had an impressive run over the past year. However, will the momentum be sustained following its upcoming earnings release scheduled for tomorrow? Read on.

Type 2 diabetes is related to an increased risk of kidney stones; however, various forms of treatment for this condition may potentially reduce the risk of kidney stones. Read further on Dynamite News:

Market value of Danish drugmaker behind Wegovy and Ozempic tops $500bn as demand soars

Danish pharmaceutical giant Novo Nordisk posted bumper profits for 2023 on Wednesday, driven by blockbuster sales of diabetes and obesity treatments that helped it become Europe's most valuable company.

Nationwide says housing market looks ‘more positive’ as prices rise 0.7%; the Danish maker of Ozempic and Wegovy predicts further strong growth in 2024

Certain reproductive characteristics in females are key risk factors for metabolic dysfunction, potentially increasing the likelihood of developing diabetes and high cholesterol in later stages of life, according to a new study.

Mounjaro will come in a four-dose device known as a KwikPen for people with type 2 diabetes or obesity